#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pseudomyxoma peritonei Necrotising myositis Univentricular heart Kearns-Sayre syndrome Malignant melanoma Congenital generalised lipodystrophy Cardiac sarcoidosis Fibrosarcoma Chondrosarcoma metastatic Colitis ulcerative Human papilloma virus immunisation Ductal adenocarcinoma of pancreas Metastatic malignant melanoma Liposarcoma Chronic inflammatory demyelinating polyradiculoneuropathy More trials…

    Learn about Rare Diseases

    Alternating hemiplegia of childhood – Life with Disease Wolfram syndrome – Diagnostics Pulmonary sarcoidosis Glomerulonephritis membranous – Basic Information Osteosarcoma metastatic – Basic Information Short-bowel syndrome – Treatment Angiosarcoma non-metastatic – Treatment Mantle cell lymphoma stage II – Life with Disease Cholangitis sclerosing – Treatment Mucopolysaccharidosis I – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fenebrutinib Ontasameran LY3848575 Lithium Sulphate, Anhydrous Al8326 ALKYLATING AGENTS Anhydrous Docetaxel F770/05 Poractant Alfa Pyridoxine Perflutren Alnus Glutinosa Pollen Calcifediol Rebisufligene Etisparvovec Treprostinil Sodium Sunvozertinib Mexiletine Hydrochloride Lixudebart L-Histidine Trehalose Dihydrate (Ph.eur.) More therapies…

    Learn about Your Condition

    Primary hyperaldosteronism Vulvovaginal dryness Cardiac sarcoidosis Cancer fatigue Corticobasal degeneration Aphthous ulcer Papilloma viral infection Supranuclear palsy Neuropathic arthropathy Trigeminal neuralgia Ventricular extrasystoles Castleman's disease Encephalitis autoimmune Vascular malformation Acute myocardial infarction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

    Not yet recruiting

    1 1 1
    Investigated Drugs:
    • Incb099280
    • Adagrasib
    France Italy Spain

  • Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Ovarian cancer
    • Head and neck cancer
    Investigated Drugs:
    • Disitamab Vedotin
    France Germany Italy Spain

  • Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Sym023
    • Sym024
    • Sym025
    Austria Belgium France Hungary Italy Romania +1

  • Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Enomimeran
    • Rbl005.3
    • Rbl007.2
    Germany Poland Spain

  • Study of Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Tiragolumab
    • Atezolizumab
    Germany

  • Safety and efficacy of Rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Rilvegostomig
    • Carboplatin
    • Cisplatin
    Germany Spain
Previous Page
1 … 21 22 23 24 25 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!